6,678 trials
Infantile Colics
Primary: Median Daily Crying Time at the End of the Treatment — 50; 55; 80 minutes
Type 2 Diabetes
Primary: Hepatic Steatosis — 6.7; NA; 8.4; 5.9 percentage of liver fat — p=0.03
Hypertension
Primary: 24-hour Average Systolic Blood Pressure — 127; 127; 126; 129 mmHg
Colorectal Cancer
Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants
Chronic Pain
Primary: Peak Plasma Concentration of Hydromorphone — 0; 0; 0; NA ng/mL
Pain
Primary: Post-op Pain With Atomized Intraperitoneal Ropivacaine (AIR) — 2.536; 3.844 millimeters — p=.098
Atrial Fibrillation
Primary: Acute Isolation of Pulmonary Veins. — 99 percent isolated pulmonary veins
Occupational; Cramp(s)
Primary: Mean Dynamic Change of Rotation at Impact — -38.4; -32.5; -36.5; NA degrees/sec
Cystic Fibrosis
Primary: Sputum Wet and Dry Weight — 6.4; 4.8; 0.20; 0.12 grams — p=.02
Hepatitis C, Chronic
Primary: Percentage of Participants Achieving Sustained Virologic Response at 24 Weeks Following Treatment Completion — 55.6 Percentage of participants
Systemic Lupus Erythematosus
Primary: Number of Participants With Positive Antibody Responses to at Least One of the 23 Pneumococcal Vaccine Serotypes 4 Weeks Post-vaccination — 32; 40 Participants
Hepatitis B, Chronic
Primary: Percentage of Participants Achieving Hepatitis C Virus Deoxyribonucleic Acid <10,000 Copies/Milliliter at Week 72 — 65.4 Percentage of participants
Non-24-Hour-Sleep-Wake Disorder
Primary: Absolute Bioavailability After a Single Oral Dose of Hetlioz™(Tasimelteon) 20mg — 38.3 Geometric Mean Ratio (%)
Apnea
Primary: Received Minute Volume (Liters) as Measured by Wright Respirometer — 6.8; 5.2 Liters — p=<0.001
Anesthesia of Mucous Membrane
Primary: Measurement of Pain Associated With Injection, in Millimeters, According to Visual Analog Scale — 38.5; 26.9 mm